Hom-Tedla M - Search Results

1

Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.

LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. LaFargue CJ, et al. Among authors: hom tedla m. Gynecol Oncol. 2022 Apr;165(1):82-89. doi: 10.1016/j.ygyno.2022.02.006. Epub 2022 Feb 23. Gynecol Oncol. 2022. PMID: 35216808 Free PMC article.

2

Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.

Jou J, Charo L, Hom-Tedla M, Coakley K, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. Jou J, et al. Among authors: hom tedla m. Gynecol Oncol. 2021 Nov;163(2):299-304. doi: 10.1016/j.ygyno.2021.09.005. Epub 2021 Sep 22. Gynecol Oncol. 2021. PMID: 34561099

3

Syndrome of inappropriate antidiuretic hormone secretion associated with an ovarian immature teratoma: A case report and review of the literature.

Hom-Tedla M, Brodsky A, Fadare O, Meriwether C, McHale M. Hom-Tedla M, et al. Gynecol Oncol Rep. 2021 Dec 16;39:100910. doi: 10.1016/j.gore.2021.100910. eCollection 2022 Feb. Gynecol Oncol Rep. 2021. PMID: 35531360 Free PMC article.

4

Persistent trophoblastic atypia on endocervical curettage found to be an epithelioid trophoblastic Tumor: A case report and review of the literature.

Brodsky AL, Hom-Tedla M, Fadare O, McHale MT. Brodsky AL, et al. Among authors: hom tedla m. Gynecol Oncol Rep. 2022 May 5;41:100994. doi: 10.1016/j.gore.2022.100994. eCollection 2022 Jun. Gynecol Oncol Rep. 2022. PMID: 35574244 Free PMC article.

5

Comparing Aggregate Fibroid Weight in Abdominal Versus Minimally Invasive Myomectomies in a Community Health System.

Mian S, Lee E, Kjelstrom S, Chaves K, Gobern J, Hom-Tedla M, Klebanoff J. Mian S, et al. Among authors: hom tedla m. J Minim Invasive Gynecol. 2025 Jan 9:S1553-4650(25)00021-4. doi: 10.1016/j.jmig.2025.01.002. Online ahead of print. J Minim Invasive Gynecol. 2025. PMID: 39798688

6

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.

Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, Burns MJ, McRae HM, Stevenson BT, Coakley KE, Ho J, Gastelum KB, Bell JC, Jones AC, Eskander RN, Dykhuizen EC, Shadel GS, Kaech SM, Hargreaves DC. Maxwell MB, et al. Among authors: hom tedla ms. Cell. 2024 Jun 20;187(13):3390-3408.e19. doi: 10.1016/j.cell.2024.04.025. Epub 2024 May 15. Cell. 2024. PMID: 38754421

7

Immunotherapy treatment landscape for patients with endometrial cancer: current evidence and future opportunities.

Hom-Tedla M, Eskander RN. Hom-Tedla M, et al. Clin Adv Hematol Oncol. 2023 Jan;21(1):27-34. Clin Adv Hematol Oncol. 2023. PMID: 36638353 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters